1,279 research outputs found

    Erratum to: Search for exclusive Higgs and Z boson decays to ϕγ and ργ with the ATLAS detector

    No full text
    One correction is noted for the paper. The calculation of an angle used to account for meson polarisation in the signal decays was not correct

    Determinants of recovery from post-COVID-19 dyspnoea: analysis of UK prospective cohorts of hospitalised COVID-19 patients and community-based controls

    Get PDF
    Background The risk factors for recovery from COVID-19 dyspnoea are poorly understood. We investigated determinants of recovery from dyspnoea in adults with COVID-19 and compared these to determinants of recovery from non-COVID-19 dyspnoea. Methods We used data from two prospective cohort studies: PHOSP-COVID (patients hospitalised between March 2020 and April 2021 with COVID-19) and COVIDENCE UK (community cohort studied over the same time period). PHOSP-COVID data were collected during hospitalisation and at 5-month and 1-year follow-up visits. COVIDENCE UK data were obtained through baseline and monthly online questionnaires. Dyspnoea was measured in both cohorts with the Medical Research Council Dyspnoea Scale. We used multivariable logistic regression to identify determinants associated with a reduction in dyspnoea between 5-month and 1-year follow-up. Findings We included 990 PHOSP-COVID and 3309 COVIDENCE UK participants. We observed higher odds of improvement between 5-month and 1-year follow-up among PHOSP-COVID participants who were younger (odds ratio 1.02 per year, 95% CI 1.01–1.03), male (1.54, 1.16–2.04), neither obese nor severely obese (1.82, 1.06–3.13 and 4.19, 2.14–8.19, respectively), had no pre-existing anxiety or depression (1.56, 1.09–2.22) or cardiovascular disease (1.33, 1.00–1.79), and shorter hospital admission (1.01 per day, 1.00–1.02). Similar associations were found in those recovering from non-COVID-19 dyspnoea, excluding age (and length of hospital admission). Interpretation Factors associated with dyspnoea recovery at 1-year post-discharge among patients hospitalised with COVID-19 were similar to those among community controls without COVID-19. Funding PHOSP-COVID is supported by a grant from the MRC-UK Research and Innovation and the Department of Health and Social Care through the National Institute for Health Research (NIHR) rapid response panel to tackle COVID-19. The views expressed in the publication are those of the author(s) and not necessarily those of the National Health Service (NHS), the NIHR or the Department of Health and Social Care. COVIDENCE UK is supported by the UK Research and Innovation, the National Institute for Health Research, and Barts Charity. The views expressed are those of the authors and not necessarily those of the funders

    Randomised trial of stable chest pain investigation : 3-year clinical and quality of life results from CE-MARC 2

    Get PDF
    Aims: Guidelines for suspected cardiac chest pain have used historical risk stratification tools, advocating invasive coronary angiography (ICA) first-line in those at highest risk. We aimed to determine whether different strategies to manage suspected stable angina affected medium-term cardiovascular event rates and patient-reported quality of life (QoL) measures. Methods: CE-MARC2, a three-arm parallel group trial, randomised patients with suspected stable cardiac chest pain and a Duke Clinical pre-test likelihood of coronary artery disease (CAD) between 10-90%. Patients were randomised to either first-line Cardiovascular Magnetic Resonance (CMR), single photon emission computed tomography (SPECT) or the UK NICE CG95(2010) guidelines-directed care. For the three arms, 1 and 3-year first-Major Adverse Cardiovascular Event (MACE) rates and QoL assessed by the Seattle Angina Questionnaire, SF12v2 and EQ-5D were recorded. Results: 1,202 patients were randomised to CMR (n=481), SPECT (n=481) and NICE (n=240). Forty-two patients (18 CMR, 18 SPECT, 6 NICE) experienced one or more MACE. The percentage rates (95% confidence intervals) of MACE in the CMR, SPECT and NICE groups at 3-years were 3.7% (2.4%, 5.8%), 3.7% (2.4%, 5.8%), 2.1% (0.9%, 4.8%) respectively. QoL scores did not significantly differ across domains. Conclusion: Despite a 4-fold increase in referrals for invasive coronary angiography, the NICE CG95 (2010) guidelines risk-stratified care strategy did not significantly reduce 3-year MACE or improve quality of life, as compared with functional imaging with CMR or SPECT